Episode 7: No Relief for Rising MS Drug Prices

February 11, 2020
Matt Hoffman
Matt Hoffman

Matt Hoffman, Senior Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive Mind Moments podcast, as well as Second Opinion on Medical World News. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Hartung, PharmD, MPH.

Episode 7 of the NeurologyLive Mind Moments podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 7, "No Relief: Rising MS Drug Prices," features an interview with Daniel M. Hartung, PharmD, MPH, associate professor of pharmacy, Oregon State University College of Pharmacy, discusses findings of a report he and colleagues compiled on rising spending in the US Medicaid program on disease-modifying therapies for multiple sclerosis, and the unique nature of their prices in the United States. Hartung's research focus involves population-level assessments on the use of prescription drugs, the effect of drug policy on health outcomes, pharmacoepidemiology, and health economics.

For more on Hartung's and colleagues' work, click here.

Click here to subscribe to the Mind Moments podcast. Thanks for listening!